News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Ironwood Pharmaceuticals Files to Begin China Phase III Trial of Linaclotide



7/18/2012 9:10:02 AM

by Richard Daverman, PhD

July 17, 2012 -- Ironwood Pharmaceuticals has filed a Clinical Trial Application with the SFDA for a China Phase III trial of linaclotide. Linaclotide is a peptide agonist aimed at treating abdominal pain in patients with irritable bowel syndrome accompanied by constipation. Ironwood, a Massachusetts pharma, still owns the China rights to the drug, although it has partnered linaclotide for much of the rest of the world. More details....

Stock Symbol: (NSDQ: IRWD)


Read at ChinaBio Today


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES